1. Design, synthesis and anti-ovarian cancer activities of thieno[2,3-d]pyrimidine based chimeric BRD4 inhibitor/nitric oxide-donator
   Yuehua Zhang et al, 2023, European Journal of Medicinal Chemistry CrossRef
2. Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells
   Marcos Quintela et al, 2023, Clinical Epigenetics CrossRef
3. Clinical perspectives of BET inhibition in ovarian cancer
   Angeliki Andrikopoulou et al, 2021, Cellular Oncology CrossRef
4. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer
   Andrew J. Wilson et al, 2018, Gynecologic Oncology CrossRef
5. The Prognostic Role of BRD4 Expression in High-Grade Serous Ovarian Cancer
   Angeliki Andrikopoulou et al, 2024, Cancers CrossRef
6. Recurrent Somatic Copy Number Alterations and Their Association with Oncogene Expression Levels in High-Grade Ovarian Serous Carcinoma
   Hillary P. Esplen et al, 2023, Life CrossRef
7. Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma
   Drumond-Bock Ana Luiza et al, 2023, Genes & Cancer CrossRef
8. The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis
   Ana Luiza Drumond-Bock et al, 2021, Molecular Cancer CrossRef
9. Exploiting epigenetic dependencies in ovarian cancer therapy
   Aisling Y. Coughlan et al, 2021, International Journal of Cancer CrossRef
10. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes
    Shariska Petersen et al, 2020, Gynecologic Oncology CrossRef
11. Therapeutic Inducers of Apoptosis in Ovarian Cancer
    Mudra Binju et al, 2019, Cancers CrossRef
12. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors
    Garrett W. Rhyasen et al, 2018, PLOS ONE CrossRef
13. Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma
    Manoela Tiago et al, 2020, British Journal of Cancer CrossRef
14. Anticancer Effects of BRD4 Inhibitor in Epithelial Ovarian Cancer
    Yeorae Kim et al, 2024, Cancers CrossRef
15. Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells
    Majid Momeny et al, 2018, Anti-Cancer Drugs CrossRef